ORGO
What one share of Organogenesis Holdings holds
Pharmaceutical Preparations
Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care and surgical and sports medicine markets.
Organogenesis Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.49 |
|---|---|
| Profit | −$0.78 |
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | $0.16 |
| Cash and investments | $0.36 |
| Book value | $1.15 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.20 | −$0.27 | $0.02 | −$0.10 | — | −$0.25 |
| 2017 | $3.11 | −$0.14 | $0.04 | −$0.09 | — | −$0.23 |
| 2018 | $2.79 | −$0.94 | $0.03 | −$0.90 | — | $0.44 |
| 2019 | $2.81 | −$0.42 | $0.06 | −$0.43 | — | $0.50 |
| 2020 | $3.04 | $0.15 | $0.16 | −$0.11 | — | $1.11 |
| 2021 | $3.50 | $0.70 | $0.23 | $0.23 | — | $1.88 |
| 2022 | $3.41 | $0.12 | $0.26 | −$0.07 | — | $2.03 |
| 2023 | $3.26 | $0.04 | $0.18 | $0.05 | — | $2.12 |
| 2024 | $3.66 | −$0.01 | $0.08 | $0.03 | — | $2.09 |
| 2025 | $4.33 | $0.15 | $0.11 | −$0.19 | — | $2.36 |